{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:25:15Z","timestamp":1781360715332,"version":"3.54.1"},"reference-count":63,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008\u20132021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develop bullous pemphigoid. Based on a multivariable analysis adjusted for age and other covariates, Alzheimer\u2019s disease and other dementias were significantly more prevalent in patients with bullous pemphigoid (p\u2009=\u20090.0013). Concomitant use of either thiazide or loop diuretics and gliptin therapy was associated with drug-associated bullous pemphigoid (p\u2009&lt;\u20090.0001 for both). While compared with sitagliptin, exposure to linagliptin and vildagliptin were associated with bullous pemphigoid with an odds ratio of 5.68 and 6.61 (p\u2009&lt;\u20090.0001 for both), respectively. These results suggest gliptins should be prescribed with caution to patients with type 2 diabetes with coexisting Alzheimer\u2019s and other dementias, or patients receiving long-term use of thiazides and loop diuretics. The use of sitagliptin over linagliptin and vildagliptin should be preferred in these patients.<\/jats:p>","DOI":"10.2340\/actadv.v104.26663","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:44:15Z","timestamp":1712292255000},"page":"adv26663","source":"Crossref","is-referenced-by-count":6,"title":["Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients"],"prefix":"10.2340","volume":"104","author":[{"given":"Dana","family":"Shalmon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Bar-Ilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Sprecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"55058","doi-asserted-by":"crossref","unstructured":"Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132: 1998-2004.","DOI":"10.1038\/jid.2012.35"},{"key":"55059","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2012.35","DOI":"10.1038\/jid.2012.35"},{"key":"55060","doi-asserted-by":"crossref","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"55061","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(12)61140-4","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"55062","doi-asserted-by":"crossref","unstructured":"Clape A, Muller C, Gatouillat G, Le Jan S, Barbe C, Pham BN, et al. Mucosal involvement in bullous pemphigoid is mostly associated with disease severity and to absence of anti-BP230 autoantibody. Front Immunol 2018; 9: 479.","DOI":"10.3389\/fimmu.2018.00479"},{"key":"55063","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2018.00479","DOI":"10.3389\/fimmu.2018.00479"},{"key":"55064","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67-77.","DOI":"10.1007\/s12016-007-0030-y"},{"key":"55065","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12016-007-0030-y","DOI":"10.1007\/s12016-007-0030-y"},{"key":"55066","doi-asserted-by":"crossref","unstructured":"Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 2818-2826.","DOI":"10.1210\/jc.2012-1205"},{"key":"55067","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1210\/jc.2012-1205","DOI":"10.1210\/jc.2012-1205"},{"key":"55068","doi-asserted-by":"crossref","unstructured":"Kang SM, Park JH. Pleiotropic benefits of DPP-4 inhibitors beyond glycemic control. Clin Med Insights Endocrinol Diabetes 2021; 14: 11795514211051698.","DOI":"10.1177\/11795514211051698"},{"key":"55069","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/11795514211051698","DOI":"10.1177\/11795514211051698"},{"key":"55070","doi-asserted-by":"crossref","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 2018; 78: 1090-1096.","DOI":"10.1016\/j.jaad.2017.12.038"},{"key":"55071","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.12.038","DOI":"10.1016\/j.jaad.2017.12.038"},{"key":"55072","doi-asserted-by":"crossref","unstructured":"Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig 2019; 10: 392-398.","DOI":"10.1111\/jdi.12877"},{"key":"55073","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdi.12877","DOI":"10.1111\/jdi.12877"},{"key":"55074","doi-asserted-by":"crossref","unstructured":"Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol 2018; 154: 1152-1158.","DOI":"10.1001\/jamadermatol.2018.2352"},{"key":"55075","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.2352","DOI":"10.1001\/jamadermatol.2018.2352"},{"key":"55076","doi-asserted-by":"crossref","unstructured":"Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155: 172-177.","DOI":"10.1001\/jamadermatol.2018.4556"},{"key":"55077","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.4556","DOI":"10.1001\/jamadermatol.2018.4556"},{"key":"55078","doi-asserted-by":"crossref","unstructured":"Plaquevent M, Tetart F, Fardet L, Ingen-Housz-Oro S, Valeyrie-Allanore L, Bernard P, et al. Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population. J Invest Dermatol 2019; 139: 835-841.","DOI":"10.1016\/j.jid.2018.10.045"},{"key":"55079","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2018.10.045","DOI":"10.1016\/j.jid.2018.10.045"},{"key":"55080","doi-asserted-by":"crossref","unstructured":"Varpuluoma O, Forsti AK, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol 2018; 138: 1659-1661.","DOI":"10.1016\/j.jid.2018.01.027"},{"key":"55081","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2018.01.027","DOI":"10.1016\/j.jid.2018.01.027"},{"key":"55082","doi-asserted-by":"crossref","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249-253.","DOI":"10.1111\/j.1468-3083.2011.04062.x"},{"key":"55083","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04062.x","DOI":"10.1111\/j.1468-3083.2011.04062.x"},{"key":"55084","doi-asserted-by":"crossref","unstructured":"Kridin K, Cohen AD. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol 2021; 85: 501-503.","DOI":"10.1016\/j.jaad.2018.09.048"},{"key":"55085","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.09.048","DOI":"10.1016\/j.jaad.2018.09.048"},{"key":"55086","doi-asserted-by":"crossref","unstructured":"Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011; 165: 593-599.","DOI":"10.1111\/j.1365-2133.2011.10386.x"},{"key":"55087","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10386.x","DOI":"10.1111\/j.1365-2133.2011.10386.x"},{"key":"55088","doi-asserted-by":"crossref","unstructured":"Di Zenzo G, Della Torre R, Zambruno G, Borradori L. Bullous pemphigoid: from the clinic to the bench. Clin Dermatol 2012; 30: 3-16.","DOI":"10.1016\/j.clindermatol.2011.03.005"},{"key":"55089","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.03.005","DOI":"10.1016\/j.clindermatol.2011.03.005"},{"key":"55090","unstructured":"Forsti AK, Jokelainen J, Timonen M, Tasanen K. Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol 2016; 96: 758-761."},{"key":"55091","doi-asserted-by":"crossref","unstructured":"Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014; 13: 477-481.","DOI":"10.1016\/j.autrev.2014.01.011"},{"key":"55092","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.autrev.2014.01.011","DOI":"10.1016\/j.autrev.2014.01.011"},{"key":"55093","doi-asserted-by":"crossref","unstructured":"Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol 2023; 14: 1196999.","DOI":"10.3389\/fimmu.2023.1196999"},{"key":"55094","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2023.1196999","DOI":"10.3389\/fimmu.2023.1196999"},{"key":"55095","doi-asserted-by":"crossref","unstructured":"Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28: 1133-1140.","DOI":"10.1111\/jdv.12366"},{"key":"55096","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12366","DOI":"10.1111\/jdv.12366"},{"key":"55097","doi-asserted-by":"crossref","unstructured":"Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol 2020; 100: adv00224.","DOI":"10.2340\/00015555-3457"},{"key":"55098","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3457","DOI":"10.2340\/00015555-3457"},{"key":"55099","doi-asserted-by":"crossref","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019; 10: 1238.","DOI":"10.3389\/fimmu.2019.01238"},{"key":"55100","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2019.01238","DOI":"10.3389\/fimmu.2019.01238"},{"key":"55101","doi-asserted-by":"crossref","unstructured":"Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne) 2018; 5: 220.","DOI":"10.3389\/fmed.2018.00220"},{"key":"55102","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2018.00220","DOI":"10.3389\/fmed.2018.00220"},{"key":"55103","doi-asserted-by":"crossref","unstructured":"Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, Gran S. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study. Br J Dermatol 2021; 184: 68-77.","DOI":"10.1111\/bjd.19022"},{"key":"55104","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19022","DOI":"10.1111\/bjd.19022"},{"key":"55105","doi-asserted-by":"crossref","unstructured":"Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015; 38: 1145-1153.","DOI":"10.2337\/dc14-2868"},{"key":"55106","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2337\/dc14-2868","DOI":"10.2337\/dc14-2868"},{"key":"55107","doi-asserted-by":"crossref","unstructured":"Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131: 631-636.","DOI":"10.1038\/jid.2010.357"},{"key":"55108","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2010.357","DOI":"10.1038\/jid.2010.357"},{"key":"55109","doi-asserted-by":"crossref","unstructured":"Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160: 1343-1345.","DOI":"10.1111\/j.1365-2133.2009.09122.x"},{"key":"55110","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09122.x","DOI":"10.1111\/j.1365-2133.2009.09122.x"},{"key":"55111","doi-asserted-by":"crossref","unstructured":"Kridin K, Avni O, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation. Arch Dermatol Res 2023; 315: 33-39.","DOI":"10.1007\/s00403-021-02317-9"},{"key":"55112","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00403-021-02317-9","DOI":"10.1007\/s00403-021-02317-9"},{"key":"55113","doi-asserted-by":"crossref","unstructured":"Gravani A, Christou P, Tigas S, Bassukas ID. Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid. An Bras Dermatol 2021; 96: 782-784.","DOI":"10.1016\/j.abd.2020.10.010"},{"key":"55114","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.abd.2020.10.010","DOI":"10.1016\/j.abd.2020.10.010"},{"key":"55115","doi-asserted-by":"crossref","unstructured":"Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. Am J Clin Dermatol 2021; 22: 891-900.","DOI":"10.1007\/s40257-021-00625-4"},{"key":"55116","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-021-00625-4","DOI":"10.1007\/s40257-021-00625-4"},{"key":"55117","doi-asserted-by":"crossref","unstructured":"Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis. Australas J Dermatol 2020; 61: e15-e21.","DOI":"10.1111\/ajd.13100"},{"key":"55118","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ajd.13100","DOI":"10.1111\/ajd.13100"},{"key":"55119","doi-asserted-by":"crossref","unstructured":"Sun L, Wang C, Wu C, Zhou Y, Wang C. Analysis of the clinical characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid. Ann Pharmacother 2022; 56: 205-212.","DOI":"10.1177\/10600280211022722"},{"key":"55120","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/10600280211022722","DOI":"10.1177\/10600280211022722"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/26663\/45715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/26663\/45715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:44:40Z","timestamp":1712292280000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/26663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":63,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.26663","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}